Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)

Background and aims Lynch syndrome (LS) patients have DNA mismatch repair deficiency and up to 80% lifetime risk of colorectal cancer (CRC). Screening of mutation carriers reduces CRC incidence and mortality. Selection for constitutional mutation testing relies on family history (Amsterdam and Bethesda Guidelines) and tumour-derived biomarkers. Initial biomarker analysis uses mismatch repair protein immunohistochemistry and microsatellite instability. Abnormalities in either identify mismatch repair deficiency but do not differentiate sporadic epigenetic defects, due to MLH1 promoter region methylation (13% of CRCs) from LS (4% of CRCs). A diagnostic biomarker capable of making this distinction would be valuable. This study compared two biomarkers in tumours with mismatch repair deficiency; quantification of methylation of the MLH1 promoter region using a novel assay and BRAF c.1799T>A, p.(Val600Glu) mutation status in the identification of constitutional mutations. Methods Tumour DNA was extracted (formalin fixed, paraffin embedded, FFPE tissue) and pyrosequencing used to test for MLH1 promoter methylation and presence of the BRAF c.1799T>A, p.(Val600Glu) mutation 71 CRCs from individuals with pathogenic MLH1 mutations and 73 CRCs with sporadic MLH1 loss. Specificity and sensitivity was compared. Findingss Unmethylated MLH1 promoter: sensitivity 94.4% (95% CI 86.2% to 98.4%), specificity 87.7% (95% CI 77.9% to 94.2%), Wild-type BRAF (codon 600): sensitivity 65.8% (95% CI 53.7% to 76.5%), specificity 98.6% (95% CI 92.4% to 100.0%) for the identification of those with pathogenic MLH1 mutations. Conclusions Quantitative MLH1 promoter region methylation using pyrosequencing is superior to BRAF codon 600 mutation status in identifying constitutional mutations in mismatch repair deficient tumours.

[1]  J. Potter,et al.  Identification of Lynch syndrome among patients with colorectal cancer. , 2012, JAMA.

[2]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[3]  M. Crépin,et al.  Evidence of constitutional MLH1 epimutation associated to transgenerational inheritance of cancer susceptibility , 2012, Human mutation.

[4]  Á. Carracedo,et al.  Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer , 2011, Gut.

[5]  R. Ward,et al.  Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. , 2011, Cancer cell.

[6]  M. Kloor,et al.  Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome , 2011, Journal of Medical Genetics.

[7]  B. Parry,et al.  Immunohistochemistry to Detect Hereditary Nonpolyposis Colorectal Cancer in Young Patients: the 7-Year Auckland Experience , 2011, Diseases of the colon and rectum.

[8]  J. Hopper,et al.  Mutation deep within an intron of MSH2 causes Lynch syndrome , 2011, Familial Cancer.

[9]  C. Boland,et al.  De novo constitutional MLH1 epimutations confer early‐onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one , 2011, International journal of cancer.

[10]  M. Clendenning,et al.  The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease , 2010, Gut.

[11]  Aung Ko Win,et al.  Risk Factors for Colorectal Cancer in Patients with Multiple Serrated Polyps: A Cross-Sectional Case Series from Genetics Clinics , 2010, PloS one.

[12]  J. Lindebjerg,et al.  Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment. , 2010, European journal of cancer.

[13]  Antoni Castells,et al.  Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. , 2010, The Journal of molecular diagnostics : JMD.

[14]  P. Hutter,et al.  Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation , 2010, Familial Cancer.

[15]  H. Morreau,et al.  Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? , 2010, BMC Cancer.

[16]  G. Evans,et al.  Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome , 2010, Histopathology.

[17]  H. Hollema,et al.  Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome , 2009, Genes, chromosomes & cancer.

[18]  N. Matsubara,et al.  Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. , 2009, Oncology reports.

[19]  M. Woods,et al.  Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis , 2009, Familial Cancer.

[20]  R. Ramesar,et al.  Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[21]  Peter W. Laird,et al.  Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening , 2008, Cancer Epidemiology Biomarkers & Prevention.

[22]  F. Radvanyi,et al.  Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based Approach Versus Molecular Screening , 2008, The American Journal of Gastroenterology.

[23]  J. Potter,et al.  The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.

[24]  M. Ebert,et al.  Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC , 2008, European Journal of Human Genetics.

[25]  A. Spurdle,et al.  Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients , 2008, Clinical Cancer Research.

[26]  P. Propping,et al.  Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome , 2008, The Journal of pathology.

[27]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[28]  A. Rustgi,et al.  The genetics of hereditary colon cancer. , 2007, Genes & development.

[29]  K. Kinzler,et al.  Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. , 2007, Journal of the National Cancer Institute.

[30]  David I. K. Martin,et al.  Inheritance of a cancer-associated MLH1 germ-line epimutation. , 2007, The New England journal of medicine.

[31]  M. Urioste,et al.  MLH1 germline epimutations in selected patients with early‐onset non‐polyposis colorectal cancer , 2007, Clinical genetics.

[32]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[33]  L. Påhlman,et al.  Somatic BRAF-V600E Mutations in Familial Colorectal Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[34]  G. Petersen,et al.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. , 2006, JAMA.

[35]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[36]  W. Frankel,et al.  Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. , 2006, Human pathology.

[37]  F. Lalloo,et al.  Is it time to abandon microsatellite instability as a pre-screen for selecting families for mutation testing for mismatch repair genes? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Kleibeuker,et al.  Decrease in mortality in Lynch syndrome families because of surveillance. , 2006, Gastroenterology.

[39]  John L Hopper,et al.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[41]  M. Andreu,et al.  Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. , 2005, JAMA.

[42]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[43]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[44]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[45]  Adopted on March.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[47]  M. Loda,et al.  A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. , 2002, Cancer research.

[48]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[49]  A. Lindblom,et al.  Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study , 2002, International Journal of Colorectal Disease.

[50]  W. Zoller,et al.  [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.

[51]  J. Wheeler,et al.  DNA mismatch repair genes and colorectal cancer , 2000, Gut.

[52]  A. de la Chapelle,et al.  Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. , 2000, The American journal of pathology.

[53]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[54]  W. Samowitz,et al.  Quantitative evaluation of CpG island methylation in hyperplastic polyps , 2010, Modern Pathology.

[55]  S. Teutsch,et al.  Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives , 2009, Genetics in Medicine.